Claims for Patent: 7,217,689
✉ Email this page to a colleague
Summary for Patent: 7,217,689
Title: | Glycosylation analogs of erythropoietin |
Abstract: | Erythropoietin analogs having at least one additional site for glycosylation, or a rearrangement of at least one site for glycosylation are disclosed. The invention also relates to DNA sequences encoding said erythropoietin analogs, and recombinant plasmids and host cells for analog expression. |
Inventor(s): | Elliott; Steven G. (Newbury Park, CA), Byrne; Thomas E. (Arlington, VA) |
Assignee: | Amgen Inc. (Thousand Oaks, CA) |
Application Number: | 08/479,892 |
Patent Claims: | 1. An analog of human erythropoietin having the in vivo biological activity of increasing hematocrit comprising an amino acid sequence which differs from the amino acid
sequence of human erythropoietin from residues 1 165 as shown in SEQ ID NO:26 at least by having one or more additional glycosylation site(s) and wherein a carbohydrate chain is attached to the additional site(s).
2. An analog of human erythropoietin comprising the amino acid sequence of human erythropoietin from residues 1 165 as shown in SEQ ID NO:26 except for one or more amino acid changes which provide for one or more additional glycosylation site(s) as compared to human erythropoietin, and the analog has more than four carbohydrate chains. 3. The analog of claims 1 or 2 wherein one additional glycosylation site is an N-linked glycosylation site having an N-linked carbohydrate chain attached thereto. 4. The analog of claims 1 or 2 wherein one additional glycosylation site is an O-linked glycosylation site having an O-linked carbohydrate chain attached thereto. 5. The analog of claims 1 or 2 which is the product of expression of an exogenous DNA sequence. 6. A DNA sequence encoding an analog of human erythropoietin according to any of claims 1 or 2. 7. A eucaryotic host cell transfected with a DNA sequence according to claim 6 in a manner allowing the host cell to express an analog of human erythropoietin. 8. A composition comprising an erythropoietin analog according to any of claims 1 or 2 together with a pharmaceutically acceptable diluent, adjuvant or carrier. 9. A method of increasing hematocrit in a patient in need thereof comprising administering a therapeutically effective amount of the composition of claim 8. 10. An analog of human erythropoietin comprising the amino acid sequence of human erythropoietin from residues 1 165 as shown in SEQ ID NO:26 except for one or more amino acid changes which provide for one or more additional glycosylation site(s) as compared to human erythropoietin, wherein one additional site is introduced at about position 30, 51, 57, 69, 88, 89, 136 or 138 and an N-linked carbohydrate chain is attached at said one additional site. 11. The analog of claim 10 wherein the one additional site is introduced at position 30. 12. The analog of claim 10 wherein the one additional site is introduced at position 51. 13. The analog of claim 10 wherein the one additional site is introduced at position 57. 14. The analog of claim 10 wherein the one additional site is introduced at position 69. 15. The analog of claim 10 wherein the one additional site is introduced at position 88. 16. The analog of claim 10 wherein the one additional site is introduced at position 89. 17. The analog of claim 10 wherein the one additional site is introduced at position 136. 18. The analog of claim 10 wherein the one additional site is introduced at position 138. 19. An analog of human erythropoietin comprising the amino acid sequence of human erythropoietin from residues 1 165 as shown in SEQ ID NO:26 except for one or more amino acid changes which provide for one or more additional glycosylation site(s) as compared to human erythropoietin, wherein one additional site is introduced at about position 123 or 125 and an O-linked carbohydrate chain is attached at said one additional site. 20. The analog of claim 19 wherein the one additional site is introduced at position 123. 21. The analog of claim 19 wherein the one additional site is introduced at position 125. 22. An analog of human erythropoietin comprising the amino acid sequence of human erythropoietin from residues 1 165 as shown in SEQ ID NO: 26 except for the amino acid changes selected from the group consisting of: Asn.sup.30Thr.sup.32 EPO; Asn.sup.51Thr.sup.53 EPO; Asn.sup.57Thr.sup.59 EPO; Asn.sup.69EPO; Asn.sup.69Thr.sup.71 EPO; Ser.sup.68Asn.sup.69Thr.sup.71 EPO; Val.sup.87Asn.sup.88Thr.sup.90 EPO; Ser.sup.87Asn.sup.88Thr.sup.90 EPO; Ser.sup.87Asn.sup.88Gly.sup.89Thr.sup.90 EPO; Ser.sup.87Asn.sup.88Thr.sup.90Thr.sup.92 EPO; Ser.sup.87Asn.sup.88Thr.sup.90Ala.sup.162 EPO; Asn.sup.69Thr.sup.71Ser.sup.87Asn.sup.88Thr.sup.90 EPO; Asn.sup.89Ile.sup.90Thr.sup.91 EPO; Ser.sup.87Asn.sup.89Ile.sup.90Thr.sup.91 EPO; Asn.sup.136Thr.sup.138 EPO: Asn.sup.138Thr.sup.140 EPO; Thr.sup.123 EPO; Thr.sup.125 EPO; and Pro.sup.124Thr.sup.125 EPO. 23. An analog of human erythropoietin comprising the amino acid sequence of human erythropoietin from residues 1 165 as shown in SEQ ID NO: 26 except for the amino acid changes Asn.sup.30Thr.sup.32Val.sup.87Asn.sup.88Thr.sup.90 EPO. 24. An analog of human erythropoietin comprising a fusion of a polypeptide fragment to the carboxy terminal end of human erythropoietin wherein the polypeptide fragment includes at least one glycosylation site having a carbohydrate chain attached thereto and wherein human erythropoietin comprises the amino acid sequence from residues 1 165 or 1 166 as shown in SEQ ID NO:26. 25. The analog of claim 24 wherein the polypeptide fragment is derived from the carboxy terminal end of human chorionic gonadotropin. 26. The analog of claim 25 wherein the polypeptide fragment has the amino acid sequence Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-G- ly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln (SEQ ID NO:25). 27. An analog of human erythropoietin having the in vivo biological activity of increasing hematocrit comprising an amino acid sequence which differs from the amino acid sequence of human erythropoietin from residues 1 165 or 1 166 as shown in SEQ ID NO:26 at least by having one or more additional glycosylation site(s) and having a carbohydrate chain attached to the additional site(s), wherein the analog is fused at its carboxy terminus to a polypeptide fragment having at least one glycosylation site with a carbohydrate chain attached thereto. 28. The analog of any of claims 10, 19, 22 or 23 fused at its carboxy terminus to a polypeptide fragment having at least one glycosylation site with a carbohydrate chain attached thereto. 29. The analog of claim 27 wherein the polypeptide fragment is fused to the carboxy terminal end of Ser.sup.87Asn.sup.88Thr.sup.90 EPO. 30. The analog of claim 27 wherein the polypeptide fragment is fused to the carboxy terminal end of Asn.sup.30Thr.sup.32Val.sup.87Asn.sup.88Thr.sup.90 EPO. 31. The analog of claim 27 wherein the polypeptide fragment is derived from the carboxy terminal end of human chorionic gonadotropin. 32. The analog of claim 27 wherein the polypeptide fragment has the amino acid sequence Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-G- ly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln (SEQ ID NO:25). 33. An analog of human erythropoietin having the in vivo biological activity of increasing hematocrit comprising an amino acid sequence which differs from the amino acid sequence of human erythropoietin from residues 1 165 as shown in SEQ ID NO:26 at least by having a deletion of one or more glycoyslation site(s) to which carbohydrate chains are attached and an addition of one or more non-naturally occurring glycosylation sites to which carbohydrate chains are attached to the additional site(s). 34. The analog of claim 33 comprising deletion of any of the N-linked carbohydrate sites in human erythropoietin and addition of an N-linked carbohydrate site at position 88. 35. The analog of claim 33 selected from the group consisting of: Gln.sup.24Ser.sup.87Asn.sup.88Thr.sup.90 EPO; Gln.sup.38Ser.sup.87Asn.sup.88Thr.sup.90 EPO; and Gln.sup.83Ser.sup.87Asn.sup.88Thr.sup.90 EPO. 36. The analog of claims 10, 19, 22, 23, 24, 27 or 33 which is the product of expression of an exogenous DNA sequence. 37. A DNA sequence encoding an analog of human erythropoietin according to any of claims 10, 19, 22, 23, 24, 27 or 33. 38. A eucaryotic host cell transfected with a DNA sequence according to claim 37 in a manner allowing the host cell to express an analog of human erythropoietin. 39. A composition comprising an erythropoietin analog according to any of claims 10, 19, 22, 23, 24, 27 or 33 together with a pharmaceutically acceptable diluent, adjuvant or carrier. 40. A method of increasing hematocrit in a patient in need thereof comprising administering a therapeutically effective amount of the composition of claim 39. |
Details for Patent 7,217,689
International Patent Family for US Patent 7,217,689
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 946122 | ⤷ Try a Trial |
South Africa | 908166 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 9505465 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 9105867 | ⤷ Try a Trial |
United States of America | 5856298 | ⤷ Try a Trial |
Ukraine | 49793 | ⤷ Try a Trial |
Slovakia | 50295 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.